Patents by Inventor Tero Kunnari
Tero Kunnari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10314815Abstract: The present invention provides a crystalline Form A of Compound 1, also referred to as Granaticin B, and pharmaceutically compositions thereof. The present invention also provides methods of treating a microbial infection, or a disease, disorder, or condition associated with abnormal cellular proliferation, using crystalline Form A of Compound 1 or pharmaceutical compositions thereof.Type: GrantFiled: December 22, 2015Date of Patent: June 11, 2019Assignee: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventor: Tero Kunnari
-
Patent number: 10081652Abstract: A method for purifying epidaunorubicin is provided. The purification method involves the removal of the impurity epi-feudomycin, which is formed as a by-product in the biotechnological production of epidaunorubicin.Type: GrantFiled: April 30, 2015Date of Patent: September 25, 2018Assignee: medac Gesellschaft für klinische Spezialpräparate mbHInventors: Holger Bindernagel, Tero Kunnari
-
Publication number: 20170360746Abstract: The present invention provides a crystalline Form A of Compound 1, also referred to as Granaticin B, and pharmaceutically compositions thereof. The present invention also provides methods of treating a microbial infection, or a disease, disorder, or condition associated with abnormal cellular proliferation, using crystalline Form A of Compound 1 or pharmaceutical compositions thereof.Type: ApplicationFiled: December 22, 2015Publication date: December 21, 2017Applicant: Sloan-Kettering Institute for Cancer ResearchInventor: Tero Kunnari
-
Patent number: 9657047Abstract: A crystalline epirubicin hydrochloride and a method for its production are provided. The method for producing the crystalline epirubicin hydrochloride includes the steps: (a) providing epirubicin hydrochloride, (b) producing a mixture containing the provided epirubicin hydrochloride and at least one alcohol selected from the group 1-butanol, 2-butanol, and 1-pentanol, and (c) crystallizing epirubicin hydrochloride from this mixture.Type: GrantFiled: May 15, 2012Date of Patent: May 23, 2017Assignee: MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBHInventor: Tero Kunnari
-
Publication number: 20170051001Abstract: A method for purifying epidaunorubicin is provided. The purification method involves the removal of the impurity epi-feudomycin, which is formed as a by-product in the biotechnological production of epidaunorubicin.Type: ApplicationFiled: April 30, 2015Publication date: February 23, 2017Applicant: Medac Gesellschaft fur Klinische Spezialpraparate mbHInventors: Holger BINDERNAGEL, Tero KUNNARI
-
Patent number: 9434756Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B. A method of producing an anthracycline using crystalline 4?-epidaunorubicin hydrochloride is also provided.Type: GrantFiled: August 14, 2014Date of Patent: September 6, 2016Assignee: medac Gesellschaft für klinische Spezialpräparate mbHInventors: Tero Kunnari, Holger Bindernagel, Sascha Weiser, Andrew Lupton, Stefan Wallert
-
Publication number: 20140357848Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B. A method of producing an anthracycline using crystalline 4?-epidaunorubicin hydrochloride is also provided.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Inventors: Tero KUNNARI, Holger BINDERNAGEL, Sascha WEISER, Andrew LUPTON, Stefan WALLERT
-
Patent number: 8822658Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B. A method of producing an anthracycline using crystalline 4?-epidaunorubicin hydrochloride is also provided.Type: GrantFiled: February 4, 2014Date of Patent: September 2, 2014Assignee: Heraeus Precious Metals GmbH & Co. KGInventors: Tero Kunnari, Holger Bindernagel, Sascha Weiser, Andrew Lupton, Stefan Wallert
-
Publication number: 20140228311Abstract: A method is provided for production of crystalline idarubicin hydrochloride, the method including the steps of: (i) producing a mixture containing (a) idarubicin hydrochloride, (b) at least one alcohol selected from 1-butanol, 2-butanol, and 1-pentanol, and (c) water; and (ii) crystallizing idarubicin hydrochloride from this mixture. A crystalline idarubicin hydrochloride is also provided characterized by a powder x-ray diffraction pattern in which at least reflexes at diffraction angles occur in the following ranges (in 2?): 7.2-7.7; 11.7-12.2; 16.2-16.7; 16.7-17.2; 19.6-20.1; 19.8-20.3; 22.2-22.7, and 22.9-23.4.Type: ApplicationFiled: September 4, 2012Publication date: August 14, 2014Applicant: HERAEUS PRECIOUS METALS GMBH & CO. KGInventor: Tero Kunnari
-
Publication number: 20140148587Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B. A method of producing an anthracycline using crystalline 4?-epidaunorubicin hydrochloride is also provided.Type: ApplicationFiled: February 4, 2014Publication date: May 29, 2014Applicant: HERAEUS PRECIOUS METALS GMBH & CO. KGInventors: Tero KUNNARI, Holger BINDERNAGEL, Sascha WEISER, Andrew LUPTON, Stefan WALLERT
-
Patent number: 8686164Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B.Type: GrantFiled: September 8, 2010Date of Patent: April 1, 2014Assignee: Heraeus Precious Metals GmbH & Co. KGInventors: Tero Kunnari, Holger Bindernagel, Sascha Weiser, Andrew Lupton, Stefan Wallert
-
Publication number: 20120309948Abstract: A crystalline epirubicin hydrochloride and a method for its production are provided. The method for producing the crystalline epirubicin hydrochloride includes the steps: (a) providing epirubicin hydrochloride, (b) producing a mixture containing the provided epirubicin hydrochloride and at least one alcohol selected from the group 1-butanol, 2-butanol, and 1-pentanol, and (c) crystallizing epirubicin hydrochloride from this mixture.Type: ApplicationFiled: May 15, 2012Publication date: December 6, 2012Applicant: HERAEUS PRECIOUS METALS GMBH & CO. KGInventor: Tero KUNNARI
-
Publication number: 20120232291Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B.Type: ApplicationFiled: September 8, 2010Publication date: September 13, 2012Applicant: Heraeus Precious Metals GmbH & Co. KGInventors: Tero Kunnari, Holger Bindernagel, Sascha Weiser, Andrew Lupton, Stefan Wallert
-
Publication number: 20060122260Abstract: The present invention relates to the finding of potentiality of aromatic polyketide intermediates in drug development and, in specific, use of these compounds in development of antiviral or anticancer medicines.Type: ApplicationFiled: November 19, 2003Publication date: June 8, 2006Inventors: Tero Kunnari, Matti Vuento
-
Publication number: 20050089954Abstract: This invention relates to the gene cluster for angucycline biosynthesis, derived from Streptomyces, and use of the genes therein to obtain antibiotics for drug screening.Type: ApplicationFiled: March 15, 2002Publication date: April 28, 2005Inventors: Kaisa Palmu, Tero Kunnari
-
Patent number: 6399583Abstract: The present invention relates to novel hybrid anthracyclines generated by cloning of fused genes in a mutated Streptomyces galilaeus strain DSM 11638. Said strain was obtained by mutagenization of the S. galilaeus wild type (ATCC 31615). The aglycone moieties of the compounds obtained are modified alkavinones, caused by the gene products introduces into the mutant, and the sugar moieties are those derived from the host strain, i.e. rhodosamine-2-deoxyfucose-2-deoxyfucose or 2-deoxyfucose-2-deoxyfucose-2-deoxyfucose, or the disaccharide or monosaccharide forms of these.Type: GrantFiled: January 11, 2000Date of Patent: June 4, 2002Assignee: Galilaeus OyInventors: Kristiina Ylihonko, Juha Hakala, Tero Kunnari